

NEWS

Contact:

Robert W. Scherrer
Chief Financial Officer
Genomas, Inc.
TEL: 860-545-4570



FOR IMMEDIATE RELEASE
13 October 2011

Genomas Awarded US Patent for PhysioType System to Predict Cardio-Metabolic Side Effects of Psychiatric Drugs

Patent Establishes Proprietary Biomarker Content for Personalized Medicine and Mental Health

HARTFORD, CT – Genomas[®], a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 8,012,718, entitled *Physiogenomic Method for Predicting Psychotropic Induced Diabetes and Metabolic Syndromes* by the US Patent and Trademark Office.

The patent covers the first gene markers of the *PIMS (Psychotropic-Induced Metabolic Symptoms) PhysioType[®]* System for the diagnosis and prevention of pre-diabetic and metabolic side effects associated with second-generation antipsychotics (SGAs). SGAs are now the leading brands in the entire pharmaceutical industry. The *PIMS PhysioType* product will be the second-generation offering in the Company's mental health franchise and complement the current, widely adopted *HILOmet PhysioType* System for management of psychotropic drugs.

Gualberto Ruaño, M.D., Ph.D., President of Genomas and co-inventor commented: "This patent is our first issued patent for a PhysioType product and represents a landmark achievement for the Company. It comprises definitive biomarkers (for innate *risk* and *protection*) correlated to weight gain induced by psychotropics and related to appetite regulation by brain peptide hormones. In the presence of ever more stringent restriction requirements by the USPTO on multi-gene systems, this patent establishes a key differentiator for Genomas in the industry of Personalized Medicine."

Research on the PhysioType System products and PhysioGenomics Technology has been published in the renowned journals *Annals of Biomedical Engineering*, *Biomarkers in Medicine*, *Clinica Chimica Acta*, *Molecular Psychiatry*, *Muscle & Nerve*, *Personalized Medicine*, *Pharmacogenomics*, *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, and *Schizophrenia Research*.

Filed in 2007, US Patent 8,012,718 complements the Company's previously issued (29 June 2010) US Patent 7,747,392 *Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients* which covers the PhysioGenomics technology platform. The Intellectual Property portfolio of Genomas encompasses these issued US Patents, 3 patent applications, 2 trademarks, and a copyright on the company's clinical informatics system.

ABOUT GENOMAS

Genomas is a biomedical company advancing DNA-Guided Medicine and personalized healthcare. The company develops revolutionary *PhysioType[®]* Systems for DNA-guided management and prescription of drugs used to treat mental illness and diabetes. *PhysioType[®]* Systems are designed to provide physicians with an unprecedented capability to select for each patient the safest and most effective drug to achieve treatment goals and enhance patient compliance. *PhysioType[®]* Systems are composed of an ensemble of inherited DNA polymorphisms genotyped by arrays and interpreted by a bioclinical algorithm in order to convey to physicians predicted comparisons of side effect risk and efficacy among drugs for the individual patient. The company's clinical pharmacogenetic tests and consultation service are provided through its *Laboratory of Personalized Health (LPH)*, an accredited and licensed high-complexity molecular diagnostic center and its *Personalized Health Portal (PHP)*, a medical informatics interface for clinician decision support. Genomas is located on the campus of Hartford Hospital. Please visit www.genomas.com for more information.

###